FDA clears new cardiac mapping solution for treating arrhythmias
Abbott has received FDA clearance for its new cardiac mapping solution fort the electrophysiology (EP) lab that provides users with 3D representations of the patient’s entire heart. The EnSite X EP System with EnSite Omnipolar Technology was designed and developed specifically with cardiac arrhythmias such as atrial fibrillation (AFib) in mind.
“As ablation therapy is increasingly used for patients battling cardiac arrhythmias, new, innovative and advanced cardiac mapping and imaging tools are essential to help physicians provide the best outcomes for their patients,” Mike Pederson, Abbott’s senior vice president of electrophysiology, said in a prepared statement.
“To continue improving outcomes for our patients, we need a system with speed, stability and accuracy,” added Amin Al-Ahmad, MD, a clinical cardiac electrophysiologist with Texas Cardiac Arrhythmia at St. David's Medical Center in Austin, Texas. “Abbott has provided us with a system that not only supports safe and effective treatment, but enhances the accuracy of maps, allowing for a clearer understanding of what is going on in the heart and what areas need to be targeted with ablation to treat arrythmias.”
According to Abbott, the new platform was designed with input from a team of electrophysiologists representing different parts of the world. Untreated arrhythmias, including AFib, can sometimes lead to heart failure or stroke, the company emphasized.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.